In a disease with slow therapeutic progress, Boehringer Ingelheim’s Jascayd launch progress raises interest in Bristol Myers Squibb’s admilparant and other late-stage idiopathic pulmonary fibrosis candidates.
In a disease with slow therapeutic progress, Boehringer Ingelheim’s Jascayd launch progress raises interest in Bristol Myers Squibb’s admilparant and other late-stage idiopathic pulmonary fibrosis candidates.